Audrey Gross; Head of Corporate Communications; Aadi Bioscience Inc. Dave Lennon; President, Chief Executive Officer, Principal Executive Officer; Aadi Bioscience In ...

New name reflects focus on accelerating portfolio of advanced ADC therapies with speed, agility and precision Upon closing of strategic transactions, cash expected ...

DAY301 is a clinical stage antibody drug conjugate targeting PTK7 in solid tumors in both adult and pediatric patients. This program has both first and best-in-class potential and is currently in ...

HWK-007 represents a differentiated opportunity to potentially be among the first next-wave ADCs in clinical development for high PTK7 expressing cancers. HWK-007 is being evaluated in IND ...

DAY301, our PTK7-targeted ADC, cleared the first dose cohort (a single-patient accelerated titration cohort) in the Phase 1a portion of the Phase 1a/b clinical trial. Day One advanced enrollment ...

DAY301, our PTK7-targeted ADC, cleared the first dose cohort (a single-patient accelerated titration cohort) in the Phase 1a portion of the Phase 1a/b clinical trial. Day One advanced enrollment in ...

It will also support initial trials of CD70-targeted PRO1160, PTK7-targeted PRO1107, and bispecific ADC PRO1286. New investors in the round included Nextech Invest, T Rowe Price Associates ...

Oral Wnt secretion inhibitors, anti-RSPO antibodies and a PTK7-targeting antibody-drug-conjugate have been developed, with some in early clinical trials, which may potentially have differential ...

["MYH9..ENSG0004627", "LMNA..ENSG0004000", "HSPG2..ENSG0003339", "EPHB4..ENSG0002050", "CSMD3..ENSG000114788", "FRMPD2..ENSG000143162", "FNDC3B..ENSG00064778 ...

This important study investigates the different mechanisms that provide instructions for a missing body part to regenerate its appropriate identity. The authors use two species of planarians to ...

Day One Biopharmaceuticals (NASDAQ: DAWN) reported its fourth-quarter 2024 earnings, highlighting significant revenue growth and strategic advancements. With a market capitalization of $1.2 billion ...